Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
HCW Biologics participates in a conference call with Maxim » 04:55
05/24/22
05/24
04:55
05/24/22
04:55
HCWB

HCW Biologics

$2.24 /

-0.01 (-0.44%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Wong on May 24 hosted by Maxim.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.24 /

-0.01 (-0.44%)

HCWB HCW Biologics
$2.24 /

-0.01 (-0.44%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.24 /

-0.01 (-0.44%)

  • 20
    Jul
Conference/Events
HCW Biologics participates in a conference call with Maxim » 11:09
05/16/22
05/16
11:09
05/16/22
11:09
HCWB

HCW Biologics

$2.00 /

+ (+0.00%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Wong on May 24 hosted by Maxim.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.00 /

+ (+0.00%)

HCWB HCW Biologics
$2.00 /

+ (+0.00%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.00 /

+ (+0.00%)

  • 20
    Jul
Hot Stocks
HCW Biologics expects cash to fund operations until end of 2023 » 07:33
05/13/22
05/13
07:33
05/13/22
07:33
HCWB

HCW Biologics

$1.99 /

+0.03 (+1.53%)

Cash and cash…

Cash and cash equivalents: On March 31, 2022, the Company's cash balance was $18.1 million, short-term investments were $17.0 million and long-term investments were $9.8 million. Investments are all U.S. Treasury bills or notes. The Company estimates that the current cash balance is sufficient to fund operations through the end of 2023.

ShowHide Related Items >><<
HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

  • 20
    Jul
Earnings
HCW Biologics reports Q1 EPS (6c) vs (69c) last year » 07:18
05/13/22
05/13
07:18
05/13/22
07:18
HCWB

HCW Biologics

$1.99 /

+0.03 (+1.53%)

Reports Q1 revenue $3.1M…

Reports Q1 revenue $3.1M vs $0 last year. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing Wong, Founder and CEO of HCW Biologics. "HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing a condition." Dr. Wong continued, "Our plan is to use difficult-to-treat cancer indications as the gateway for clinical development of our lead product candidate, HCW9218. In preclinical studies, we have demonstrated that HCW9218 can effectively reduce therapy-induced cancer and normal tissue cellular senescence to augment the anti-tumor activities of chemotherapies and alleviate their side effects. In addition, HCW9218 has been shown to significantly enhance anti-tumor activity of immune checkpoint therapies in a preclinical setting." Dr. Wong further stated, "We believe that HCW9218 also has potential as a treatment for a broad range of age-related pathologies beyond cancer, through our discovery that HCW9218 can reduce accumulated senescent cells due to the naturally aging process or metabolic dysfunction, leading to the improvement of health span of experimental animals."

ShowHide Related Items >><<
HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$1.99 /

+0.03 (+1.53%)

  • 20
    Jul
Hot Stocks
HCW Biologics to present two groups of novel immunotherapeutics » 07:56
05/05/22
05/05
07:56
05/05/22
07:56
HCWB

HCW Biologics

$2.26 /

-0.07 (-3.00%)

HCW Biologics is…

HCW Biologics is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon discovery platform at the 105th Annual Meeting of the American Association of Immunologists, AAI, or Immunology 2022. "HCW Biologics has invented a unique solution for providing clinical-grade fusion proteins for therapeutic use," stated Dr. Hing Wong, Founder and CEO of HCW Biologics. "Immunology 2022 is our opportunity to showcase the power and versatility of our TOBI discovery platform. The first program will feature the benefits of the use of our fusion proteins without the need of feeder cells to address the challenges for supporting a multiple-dose infusion of memory-like NK cells in the clinic for cancer." Dr. Wong continued, "Immunology 2022 also provides us with an ideal audience for the introduction to our program for the expansion of regulatory T cells for the treatment of autoimmune and inflammatory diseases. The benefits of Treg cells in the treatment of inflammatory diseases are well-known, but manufacturing these therapies are labor intensive, lack consistency, and are difficult to scale. HCW Biologics has developed an approach that does not rely on magnetic beads. We also showcase our proprietary human monoclonal antibodies for generating target-specific Treg cells. We believe our unique approach could potentially open up Treg therapy as an adoptive cell therapy that could address a broad range of inflammatory pathologies." Oral and Poster Presentation for Expansion of Memory-Like NK Cells: Title: "A feeder cell-free activation and expansion strategy to generate memory-like NK cells sufficient for off-the-shelf multi-dose adoptive cell therapy." Title: "Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy."

ShowHide Related Items >><<
HCWB HCW Biologics
$2.26 /

-0.07 (-3.00%)

HCWB HCW Biologics
$2.26 /

-0.07 (-3.00%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.26 /

-0.07 (-3.00%)

  • 20
    Jul
Hot Stocks
HCW Biologics CEO to be featured speaker at CEB-2022 » 07:38
04/19/22
04/19
07:38
04/19/22
07:38
HCWB

HCW Biologics

$2.74 /

+0.02 (+0.74%)

HCW Biologics announced…

HCW Biologics announced that Hing Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology taking place in Boston, Massachusetts on April 18-20, 2022. Dr. Wong's presentation entitled, "Bifunctional Immunotherapeutic HCW9218 for Cancer and Inflammaging," will highlight preclinical data from in vivo animal studies demonstrating the ability of the Company's lead investigational candidate, HCW9218, to both enhance the anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence and eliminating TGF-beta and its immunosuppressive effects. The presentation will highlight information contained in a pivotal paper recently published in a peer-reviewed journal entitled, "Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell Mediated Reduction of Therapy Induced Senescent Cells." Chaturvedi P., et al., Molecular Therapy, 2022; 30:1171-1187. Dr. Wong will also share for the first time preclinical data showing that HCW9218 is a promising senolytic and senomorphic agent for age-related pathologies. Dr. Wong stated, "Chemotherapies seed cancer relapses and metastases, and trigger inflammation-based side effects in treated patients by inducing cancer senescent cells and normal tissue cellular senescence. We have previously demonstrated, in preclinical studies, that HCW9218 can effectively reduce therapy-induced cancer and normal tissue cellular senescence to augment the anti-tumor activities of chemotherapies and alleviate their side effects. Thus, we believe HCW9218 can make chemotherapy cancer treatments work better with fewer side effects and extend the health span for cancer survivors. Now, we discovered that HCW9218 can also reduce accumulated senescent cells due to the naturally aging process or metabolic dysfunction leading to the improvement of heath span of experimental animals. I am thrilled to share this transformative discovery with the scientific community at the CEB-2022 conference." In explaining why he selected CEB-2022 as the venue to feature HCW Biologics' work on anti-inflammaging, Dr. Wong stated, "CEB-2022 is a gathering of scientific experts from around the world who come together to discuss innovation and advancement in the fields of cell and molecular biology. HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing the condition. The conference provides an audience who will be able to appreciate what we believe is a novel approach backed by breakthrough data." HCW9218 will soon reach the clinical development stage for cancer. The Company expects to gain human data from two clinical trials that will guide the future development of HCW9218 for other age-related pathologies.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.74 /

+0.02 (+0.74%)

HCWB HCW Biologics
$2.74 /

+0.02 (+0.74%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.74 /

+0.02 (+0.74%)

  • 20
    Jul
Over a quarter ago
Hot Stocks
HCW Biologics expects cash to fund operations until end of 2023 » 07:12
03/28/22
03/28
07:12
03/28/22
07:12
HCWB

HCW Biologics

$2.60 /

+0.215 (+9.01%)

On December 31, 2021, the…

On December 31, 2021, the Company's cash balance was $11.7M , short-term investments were $25M and long-term investments were $9.9M. The net proceeds from the IPO were $49.2M. The Company estimates that it has sufficient cash to fund operation expenses to the end of 2023. This estimated cash runway does not include potential sources of non-dilutive financing, which may be obtained from new or existing out-licensing agreements.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

  • 20
    Jul
Earnings
HCW Biologics reports Q4 net loss $3.2M vs $2.1M last year » 07:11
03/28/22
03/28
07:11
03/28/22
07:11
HCWB

HCW Biologics

$2.60 /

+0.215 (+9.01%)

Dr. Hing Wong, the…

Dr. Hing Wong, the Founder and CEO of HCW Biologics, stated, "We accomplished a number of significant achievements in the past year. We fortified our balance sheet through an initial public offering. We advanced our clinical development programs, overcoming headwinds from the COVID-19 pandemic, supply chain disruptions, and critical supply shortages. We begin 2022 poised to initiate multiple clinical trials to evaluate HCW9218 in cancer indications. We are hopeful later this year we begin to see human data that demonstrate the potential for our immunotherapeutics in the treatment of chemotherapy-resistant cancer, and validate our focus on the elimination of cellular senescence, which is the etiology for many age-related diseases."

ShowHide Related Items >><<
HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.60 /

+0.215 (+9.01%)

  • 20
    Jul
Initiation
HCW Biologics initiated with a Buy at Maxim » 07:59
03/24/22
03/24
07:59
03/24/22
07:59
HCWB

HCW Biologics

$2.26 /

+0.13 (+6.10%)

Maxim analyst Michael…

Maxim analyst Michael Okunewitch initiated coverage of HCW Biologics with a Buy rating and $4.00 price target. The analyst notes that the aging and longevity space has seen significant investment, and cellular senescence in particular represents an area of interest for big pharma partnering. Okunewitch adds that HCW's immunotherapeutic approach may have advantages through correcting the clearance and regulatory mechanisms that degrade with age, addressing a broad range of high value indications.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.26 /

+0.13 (+6.10%)

HCWB HCW Biologics
$2.26 /

+0.13 (+6.10%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.26 /

+0.13 (+6.10%)

  • 20
    Jul
Initiation
HCW Biologics initiated with a Buy at Maxim » 07:47
03/24/22
03/24
07:47
03/24/22
07:47
HCWB

HCW Biologics

$2.26 /

+0.13 (+6.10%)

Maxim analyst Michael…

Maxim analyst Michael Okunewitch initiated coverage of HCW Biologics with a Buy rating and $4 price target.

ShowHide Related Items >><<
HCWB HCW Biologics
$2.26 /

+0.13 (+6.10%)

HCWB HCW Biologics
$2.26 /

+0.13 (+6.10%)

  • 20
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.